BERLIN (Reuters) – Morphosys said its takeover by Novartis was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company’s share price on Monday.
“The planned acquisition by Novartis is progressing steadily,” a Morphosys spokesperson said in an emailed response to Reuters. “We remain confident in the benefit-risk profile of the combination of pelabresib and ruxolitinib.”
(Reporting by Patricia Weiss, Writing by Rachel More, Editing by Andrey Sychev)
Comments